BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
4/12/2024 4:45:44 PM | Browse: 260 | Download: 921
 |
Received |
|
2023-12-15 15:54 |
|
Peer-Review Started |
|
2023-12-15 15:54 |
|
First Decision by Editorial Office Director |
|
2024-02-19 01:37 |
|
Return for Revision |
|
2024-02-19 01:37 |
|
Revised |
|
2024-02-23 07:17 |
 |
Publication Fee Transferred |
|
|
|
Second Decision by Editor |
|
2024-03-28 01:51 |
|
Second Decision by Editor-in-Chief |
|
|
|
Final Decision by Editorial Office Director |
|
2024-03-28 02:50 |
|
Articles in Press |
|
2024-03-28 02:50 |
|
Edit the Manuscript by Language Editor |
|
|
|
Typeset the Manuscript |
|
2024-04-03 06:11 |
|
Publish the Manuscript Online |
|
2024-04-12 16:45 |
| ISSN |
1007-9327 (print) and 2219-2840 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
©The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Gastroenterology & Hepatology |
| Manuscript Type |
Editorial |
| Article Title |
Immune checkpoint inhibitor-associated gastritis: Patterns and management
|
| Manuscript Source |
Invited Manuscript |
| All Author List |
Jing Lin, Zhong-Qiao Lin, Shi-Cheng Zheng and Yu Chen |
| ORCID |
|
| Funding Agency and Grant Number |
| Funding Agency |
Grant Number |
| Joint Funds for the Innovation of Science and Technology, Fujian Province |
2021Y9227 |
| Natural Science Foundation of Fujian Province |
2023J011254 |
| The Science Foundation for The Excellent Youth Scholars of Fujian Provincial Health Commission |
2022ZQNZD009 |
| The Special Research Funds for Local Science and Technology Development Guided by Central Government |
2023L3020 |
| Fujian Medical University Student Innovation and Entrepreneurship Training Project |
JC2023191 |
|
| Corresponding Author |
Yu Chen, MD, Chief Doctor, Department of Medical Oncology, Clinical Oncology School of Fujian Medical University, Fujian Cancer Hospital, No. 420 Fumu Road, Jin’an District, Fuzhou 350000, Fujian Province, China. chenyu1980@fjmu.edu.cn |
| Key Words |
Immunotherapy; Immune checkpoint inhibitor; Immune-related adverse events; Immune checkpoint inhibitor-related gastritis |
| Core Tip |
Immune checkpoint inhibitor (ICI)-related gastritis is rare but may lead to serious complications such as gastrorrhagia. Biopsy under esophagogastroduodenoscopy is the gold standard for diagnosis. Specifically, this article discusses strategies for treating ICI-related gastritis, including early recognition, pathological diagnosis, management interventions, and rechallenge with immunotherapy, providing clinicians with valuable consultations to enable cancer patients to benefit early from treatment. |
| Publish Date |
2024-04-12 16:45 |
| Citation |
Lin J, Lin ZQ, Zheng SC, Chen Y. Immune checkpoint inhibitor-associated gastritis: Patterns and management. World J Gastroenterol 2024; 30(14): 90865
|
| URL |
https://www.wjgnet.com/1007-9327/full/v30/i14/1941.htm |
| DOI |
https://dx.doi.org/10.3748/wjg.v30.i14.1941 |
All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.
